Join our community of smart investors

Abcam trims full-year guidance

The antibody specialist has pulled back on full-year growth expectations, causing a nervous reaction from investors
Abcam trims full-year guidance

Even though Abcam’s (ABC) half-year numbers were as expected, lower-than-expected guidance for the full year prompted a sharp de-rating in the stock on results day. Bosses now expect yearly revenue growth to be in line with the first half, while expectations for annual adjusted cash profit margins have moderated from 36 per cent to 35 per cent due to higher investments.

IC TIP: Hold at 1,156p

To continue reading...
Join our Community of Smart Investors
  • Independent full-length company analysis
  • Actionable investment ideas and recommendations
  • Expert investment tools and data
  • Stock screens from Algy Hall
Have an account? Sign in